Apogee Therapeutics (NASDAQ:APGE) Earns “Buy” Rating from Guggenheim
Apogee Therapeutics (NASDAQ:APGE – Get Free Report)‘s stock had its “buy” rating reissued by analysts at Guggenheim in a research report issued to clients and investors on Monday,Benzinga reports. Several other research firms also recently commented on APGE. Canaccord Genuity Group began coverage on shares of Apogee Therapeutics in a research note on Monday, November […]
Apogee Therapeutics (NASDAQ:APGE – Get Free Report)‘s stock had its “buy” rating reissued by analysts at Guggenheim in a research report issued to clients and investors on Monday,Benzinga reports. Several other research firms also recently commented on APGE. Canaccord Genuity Group began coverage on shares of Apogee Therapeutics in a research note on Monday, November […]
